Substipharm acquires IMOJEV® SUBSTIPHARM is proud to announce that it entered into an agreement to acquire the Japanese Encephalitis vaccine IMOJEV® from Sanofi for an undisclosed amount. IMOJEV® is indicated for the prevention of Japanese Encephalitis in both adults and children, and is currently marketed in Australia, Brunei, Cambodia, Hong Kong, Indonesia, Malaysia, Myanmar, Philippines, Taiwan, Thailand Singapore, South Korea, Sri Lanka, Vietnam. As a French based privately-owned company, SUBSTIPHARM will not only dedicate all efforts in consolidating IMOJEV®’s market share in its current territories but will also heavily invest to extend this vaccine availability globally.